Overview:
The management of hormone receptor–positive/HER2-negative metastatic breast cancer continues to evolve with the introduction of novel endocrine agents, expanding biomarker use, and increasingly personalized combination strategies. New evidence for oral selective estrogen receptor degraders (SERDs), emerging estrogen receptor–targeted therapies, and pathway-directed treatments is refining how clinicians approach treatment sequencing across lines of therapy. As new clinical data emerge, clinicians must weigh efficacy, safety, and patient-selection factors to deliver individualized care.
This online, CME-certified Oncology Town Hall Series: Oral
SERDs in HR+/HER2- Metastatic Breast Cancer - What the Latest Data Really Tell
Us will bring together expert faculty to review the key findings and discuss
their potential implications for current practice. Following the 2026 National
Oncology Meeting in Chicago, the program will feature dynamic discussions,
practical insights, and updates from pivotal clinical trials. The interactive
format is designed to encourage thoughtful exchange and provide actionable
guidance for optimizing patient care.
Learning Objectives:
Upon completion of this activity, learners will be better prepared
to:
- Identify approved and emerging oral SERDs for the management of HR+/HER2– breast cancer.
- Assess emerging clinical trial and real-world evidence to gain practical insights into the appropriate use of oral SERD-based treatment strategies for patients with HR+/HER2– MBC.
- Integrate clinical trial data, real-world evidence, and patient- and disease-specific factors to inform personalized treatment decisions for patients with HR+/HER2– MBC.
Target Audience:
This educational program is primarily directed toward a
global audience of medical oncologists, advanced practice providers, nurses and
other HCPs who are involved in the management of patients with advanced or
metastatic breast cancer.